Baxter International Inc (BAX) : Isthmus Partners scooped up 77,433 additional shares in Baxter International Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 10, 2016. The investment management firm now holds a total of 157,863 shares of Baxter International Inc which is valued at $7,185,924.Baxter International Inc makes up approximately 2.39% of Isthmus Partners’s portfolio.
Other Hedge Funds, Including , Alps Advisors Inc sold out all of its stake in BAX during the most recent quarter. The investment firm sold 530,929 shares of BAX which is valued $24,167,888. Osher Van De Voorde Investment Management sold out all of its stake in BAX during the most recent quarter. The investment firm sold 174,160 shares of BAX which is valued $7,927,763.Schwab Charles Investment Management Inc reduced its stake in BAX by selling 323,223 shares or 16.33% in the most recent quarter. The Hedge Fund company now holds 1,655,910 shares of BAX which is valued at $74,631,864. Baxter International Inc makes up approx 0.10% of Schwab Charles Investment Management Inc’s portfolio.Parkwood reduced its stake in BAX by selling 1,067 shares or 7.64% in the most recent quarter. The Hedge Fund company now holds 12,904 shares of BAX which is valued at $581,583. Baxter International Inc makes up approx 0.10% of Parkwood’s portfolio.Rand Wealth boosted its stake in BAX in the latest quarter, The investment management firm added 400 additional shares and now holds a total of 5,900 shares of Baxter International Inc which is valued at $260,898. Baxter International Inc makes up approx 0.04% of Rand Wealth’s portfolio.
Baxter International Inc closed down -0.05 points or -0.11% at $45.47 with 2,52,29,832 shares getting traded on Monday. Post opening the session at $45.39, the shares hit an intraday low of $45.3 and an intraday high of $45.875 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Baxter International Inc reported $0.36 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on Apr 26, 2016. Analyst had a consensus of $0.29. The company had revenue of $2375.00 million for the quarter, compared to analysts expectations of $2351.22 million. The company’s revenue was down -1.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $1.00 EPS.
Investors should note that on May 3, 2016, Baxter International Inc announced a cash dividend of $0.1300. The company’s management has announced Jun 1, 2016 as the ex-dividend date and fixed the record date on Jun 3, 2016. The payable date has been fixed on Jul 1, 2016.
Many Wall Street Analysts have commented on Baxter International Inc. Company shares were Reiterated by RBC Capital Mkts on Apr 27, 2016 to “Sector Perform”, Firm has raised the Price Target to $ 47 from a previous price target of $40 .Baxter International Inc was Upgraded by Piper Jaffray to ” Overweight” on Apr 14, 2016.
Baxter International Inc. (Baxter) is a diversified healthcare company. The Company operates in two segments: BioScience segment which include three commercial franchises: Hemophilia BioTherapeutics and BioSurgery and Medical Products segment which include four commercial franchises: Fluid Systems Renal Specialty Pharmaceuticals and BioPharma Solutions. Its BioScience processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies alpha-1 antitrypsin deficiency burns and shock and other chronic and acute blood-related conditions and biosurgery products. Its Medical Products manufactures intravenous (IV) solutions and administration sets premixed drugs and drug-reconstitution systems pre-filled vials and syringes for injectable drugs IV nutrition products infusion pumps and inhalation anesthetics. Its products are used in hospitals kidney dialysis centers and nursing homes among others.